NCT05383833Completed
Creatine to Augment Bioenergetics in Alzheimer's
Source: ClinicalTrials.gov · Last updated 14 Aug 2024
Brief summary (registry, in English)
By doing this study, researchers hope to see if creatine monohydrate is a helpful treatment for people with Alzheimer's disease.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 20 Apr 2022
- Start date
- 12 Dec 2022
- Primary completion date
- 14 May 2024
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Alzheimer disease
- NCT number
- NCT05383833
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 12 Dec 2022 to the primary completion date, 14 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinical trial or investigational drug or therapy participation within 30 days of the screening visit
Other illness
- Insulin-requiring diabetes, cancer requiring chemotherapy or radiation within the past 5 years, or recent cardiac event (i.e., heart attack, etc.)
- Other neurodegenerative disease
- Ongoing renal disorder or abnormal renal or liver function
Other
- Unable to undergo MRI
- Non-English speakers
- Inability to perform strength testing
- Weight \> 350 lbs.
Who the study is looking for
- Diagnosed cognitive impairment due to Alzheimer's disease
- Agreed cooperation from a study partner
- Speaks English as primary language
- Age 60 to 90
- Stable medication for ≥30 days
- BMI ≥ 20.0kg/m2
Age in the registry: 60 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Unknown status |
Related publications
- Bioenergetic data from a creatine monohydrate pilot trial in Alzheimer's disease.Alzheimers Dement (N Y) · 2026 · PMID 41737290
This page is information, not medical advice. Discuss any trial with your doctor.